Phil Shackley BA MSc PhD
Reader in Health Economics
University of Sheffield
Regent Court, 30 Regent Street
Sheffield, S1 4DA
Tel: (+44) (0)114 222 2992
Fax: (+44) (0)114 222 0749
I was appointed Reader in Health Economics in January 2012, having previously held Senior Lecturer appointments at the Universities of Sheffield (2006-2011) and Newcastle (2002-2006). Prior to that I worked as a Lecturer at the University of Sheffield (1996–2002) and as a Research Fellow at the University of Aberdeen (1991–1996).
- Developing and applying the contingent valuation methodology, in particular the technique of willingness to pay. Applications include: estimating the social value of a quality adjusted life year (QALY); using willingness to pay values to aid priority setting in publicly-financed health care systems; investigating how willingness to pay can and should be used alongside randomised trials; the use of willingness to pay to evaluate the benefits of public health interventions such as the fluoridation of drinking water supplies and the supplementation of flour with folic acid; evaluating minimally invasive surgery; assessing patient preferences for diagnostic radiology; and assessing preferences for an expanded newborn screening programme.
- The identification, measurement and valuation of (dis)benefits that are not captured in the QALY approach. Applications include: assessing the value of patient health cards; eliciting patient preferences for out-of-hours primary care services; establishing and quantifying the preferences of mental health service users for day hospital care; eliciting patient preferences for the organisation of vascular services; and assessing preferences for access to a general practitioner.
- The application of economic evaluation techniques to assess the efficiency of health care programmes and interventions. Applications include: screening in primary care; antenatal screening; management of lower respiratory tract infection in general practice; computerised cognitive behavioural therapy for anxiety and depression; methods for assessing patients with intermittent claudication; drug treatments for epilepsy; stroke incidence and prevention in Tanzania; venous leg ulcers; and treating upper limb spasticity due to stroke with botulinum toxin.
I teach health economics on a number of modules on MSc Health Economics and Decision Modelling, MSc Economics and Health Economics and MSc International Health Technology Assessment, Pricing and Reimbursement. I am the Director of Teaching for HEDS and the Academic Lead for Teaching Quality for ScHARR.
I am interested in supervising research students in topics related to my research interests above.
- Member of the Higher Education Academy (formerly the Institute for Learning and Teaching in Higher Education)
- Member of the UK Health Economists' Study Group
- Member of the International Health Economics Association
- Examining the feasibility of measuring process utilities associated with different models of care for obese leg ulcer patients.
- The design, development, commissioning and evaluation of patient focused vascular services.
- Evaluation of workplace interventions for long latency diseases.
Phil Shackley is based in Health Economics and Decision Science (HEDS).
- Rowen D, Brazier J, Mukuria C, Keetharuth A, Risa Hole A, Tsuchiya A, Whyte S & Shackley P (2016) Eliciting Societal Preferences for Weighting QALYs for Burden of Illness and End of Life. Medical Decision Making, 36(2), 210-222.
- Shackley P & Dixon S (2013) The random card sort method and respondent certainty in contingent valuation: An exploratory investigation of range bias. Health Economics (United Kingdom).
- Shackley P, Shaw L, Price C, van Wijck F, Barnes M, Graham L, Ford GA, Steen N & Rodgers H (2012) Cost-effectiveness of treating upper limb spasticity due to stroke with botulinum toxin type a: Results from the botulinum toxin for the upper limb after stroke (BoTULS) trial. Toxins, 4(12), 1415-1426.
- Shaw LC, Price CI, van Wijck FM, Shackley P, Steen N, Barnes MP, Ford GA, Graham LA, Rodgers H & BoTULS Investigators (2011) Botulinum Toxin for the Upper Limb after Stroke (BoTULS) Trial: effect on impairment, activity limitation, and pain.. Stroke, 42(5), 1371-1379.
- Donaldson C, Baker R, Mason H, Jones-Lee M, Lancsar E, Wildman J, Bateman I, Loomes G, Robinson A, Sugden R, Prades JL, Ryan M, Shackley P & Smith R (2011) The social value of a QALY: raising the bar or barring the raise?. BMC Health Serv Res, 11, 8.
- Michaels JA, Campbell B, King B, Palfreyman SJ, Shackley P & Stevenson M (2009) Randomized controlled trial and cost-effectiveness analysis of silver-donating antimicrobial dressings for venous leg ulcers (VULCAN trial).. Br J Surg, 96(10), 1147-1156.
- Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell SJL, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, Roberts R, Shackley P, Shen J, Smith DF, Smith PEM, Smith CT, Vanoli A, Williamson PR & SANAD Study Grp (2007) The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. LANCET, 369(9566), 1000-1015.
- Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW, Cramp C, Cockerell OC, Cooper PN, Doughty J, Eaton B, Gamble C, Goulding PJ, Howell SJL, Hughes A, Jackson M, Jacoby A, Kellett M, Lawson GR, Leach JP, Nicolaides P, Roberts R, Shackley P, Shen J, Smith DF, Smith PEM, Smith CT, Vanoli AA, Williamson PR & SANAD Study Grp (2007) The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. LANCET, 369(9566), 1016-1026.
- Shackley P & Donaldson C (2002) Should we use willingness to pay to elicit community preferences for health care? New evidence from using a 'marginal' approach.. J Health Econ, 21(6), 971-991.
- Stewart JM, O'Shea E, Donaldson C & Shackley P (2002) Do ordering effects matter in willingness-to-pay studies of health care?. J Health Econ, 21(4), 585-599.